In an early onset allergic USA patient, independently of blood eosinophil count, omalizumab will be the first choice while in a late onset non-allergic USA patient with eosinophilia, an anti-IL5/IL5Rα, or dupilumab will be considered. This evidence concerns the gene IL5 and Increased total eosinophil count.